Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

67053 1513184208HCLSReviewBulgariaDecember2017.pdf
Energy Boardroom

Novo, Teva, Shire, Actavis and Mylan post Q1 growth as Endo gets pummeled

01.05.2014 / Fierce Pharma

Earnings were kind to many of pharma's midsize players between Wednesday and Thursday, with several drugmakers–Endo excluded–posting growth. But not all of those companies reaped the sales they expected to, with Novo Nordisk and Teva falling into that category. Big changes may be in store, however, at least for a few of them–Shire and Mylan, for two, may soon find themselves in the middle of pharma's recent M&A storm.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: